Mach 1 Financial Group LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Mach 1 Financial Group LLC bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 4,393 shares of the biopharmaceutical company’s stock, valued at approximately $841,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. grew its stake in Alnylam Pharmaceuticals by 0.3% in the third quarter. Vanguard Group Inc. now owns 11,656,831 shares of the biopharmaceutical company’s stock valued at $2,064,425,000 after purchasing an additional 30,608 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Alnylam Pharmaceuticals by 6.0% in the third quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company’s stock worth $1,139,074,000 after acquiring an additional 364,021 shares in the last quarter. Northern Trust Corp boosted its holdings in Alnylam Pharmaceuticals by 3.3% in the third quarter. Northern Trust Corp now owns 797,700 shares of the biopharmaceutical company’s stock worth $141,273,000 after acquiring an additional 25,230 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in Alnylam Pharmaceuticals by 12.9% in the third quarter. Ameriprise Financial Inc. now owns 706,200 shares of the biopharmaceutical company’s stock worth $125,066,000 after acquiring an additional 80,862 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in Alnylam Pharmaceuticals by 2.4% in the third quarter. Massachusetts Financial Services Co. MA now owns 688,228 shares of the biopharmaceutical company’s stock worth $121,885,000 after acquiring an additional 15,831 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 2.3 %

Shares of Alnylam Pharmaceuticals stock traded down $3.41 on Tuesday, reaching $143.95. The company’s stock had a trading volume of 477,037 shares, compared to its average volume of 768,820. The company has a market capitalization of $18.13 billion, a P/E ratio of -41.39 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $218.88. The stock has a 50-day moving average price of $150.22 and a 200-day moving average price of $165.63.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.10. The business had revenue of $439.72 million during the quarter, compared to analysts’ expectations of $439.38 million. During the same quarter last year, the firm earned ($1.68) earnings per share. The firm’s quarterly revenue was up 31.2% compared to the same quarter last year. Sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -4.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ALNY has been the subject of several recent analyst reports. Wolfe Research initiated coverage on Alnylam Pharmaceuticals in a report on Thursday, February 15th. They issued a “peer perform” rating for the company. The Goldman Sachs Group downgraded Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $230.00 to $173.00 in a report on Friday, February 16th. Wells Fargo & Company decreased their target price on Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating for the company in a report on Friday, February 16th. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 8th. Finally, JPMorgan Chase & Co. lifted their target price on Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the stock a “neutral” rating in a report on Thursday, February 1st. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $215.88.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.